- Optimi Health Corp. (OPTI) has completed the largest legal natural psilocybin harvest in Canadian history
- The company has a commercially harvested yield of more than 150 kg of Panaeolus cyanescens and Psilocybe cubensis
- Optimi will use the mushrooms to develop its on-site extraction methods and finalize its naturally derived psilocybin offerings this fall
- Optimi Health Corp (OPTI) is trading steady at $0.40 as of 9:40 am ET
Optimi Health Corp. (OPTI) has completed the largest legal natural psilocybin harvest in Canadian history.
Building off its first official harvest on May 2022 which produced various strains of psilocybin for lab analysis and early-stage supply agreements, the company reported that it has a commercially harvested yield of more than 150 kg of Panaeolus cyanescens and Psilocybe cubensis.
All Optimi mushroom products are grown from the company’s psilocybin genetic bank and are grown in EU-GMP compliant clean rooms that undergo almost 300 different analytical tests post-harvest.
Optimi’s Chief Science Officer, Justin Kirkland, stated that the company’s mushrooms are some of the most tested products on the planet as the team crosses the lines between pharmaceutical, agriculture, botanical, and food testing quality assays.
“This yield gives us the capacity and scale we need to advance our analytical schedule while also developing our product pipeline.”
The company’s Chief Operations Officer, Bryan Safarik, added that the yield exceeded expectations in terms of quality and quantity.
“By controlling and tracking all of the inputs digitally, we are able to consistently grow psilocybin-containing mushrooms at a much higher potency to maximize the amount of naturally occurring psilocybin within the mushroom.”
He noted that the company’s controls are a key differentiator for what the company offers the global market. The higher the potency, the less biomass is needed to achieve the desired amount of pure psilocybin API. This means the team can create considerably more natural psilocybin per square foot than a typical black market grow. More psilocybin in less space achieves more revenue per square foot.
Optimi will use the mushrooms to develop its on-site extraction methods and finalize its naturally derived psilocybin offerings this fall. The company is working to supply various upcoming phase 1 & 2 clinical trials to build out the required human safety data in healthy Canadians, and eventually patients suffering from depression, anxiety, and PTSD.
Optimi Health Corp. (OPTI) is a Vancouver-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin, synthetic psychedelic substances and functional mushrooms that focus on the health and wellness markets.
Optimi Health Corp (OPTI) is trading steady at $0.40 as of 9:40 am ET.
